bio sketch column
Dr. Nicholas A Meanwell received his PhD degree from the University of Sheffield under the supervision of Dr. D Neville Jones and completed a post-doctoral fellowship with Prof. Carl R Johnson before joining Bristol-Myers Squibb in 1982. His team has discovered the HIV-1 attachment inhibitor temsavir and its prodrug fostemsavir, the HCV NS3 protease inhibitor, asunaprevir, and the HCV NS5A inhibitor, daclatasvir, both of which are approved in Japan for the treatment HCV genotype 1b infection. He is the author or co-author of more than 195 articles and is named as an inventor on 144 garnated patents. He is a co-recipient of a 2014 PhRMA Research and Hope Award for Biopharmaceutical Industry Research, recipient of the 2015 Philip S Portoghese Medicinal Chemistry Lectureship Award and was inducted into the ACS Division of Medicinal Chemistry Hall of Fame in 2015.